

A Study of Brenipatide in Participants With Alcohol Use Disorder

NCT07219953

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	1,100 participants

Key Eligibility Criteria

Inclusion (7)

- Participant must be a minimum of 20 years of age for the investigative sites in Japan.
 - Are seeking treatment and are motivated to stop or cut down on drinking.
 - Are reliable and willing to make themselves available for the duration of the study and attend required study visits, and are willing and able to follow study procedures as required, such as
 - self-inject study intervention Note: Participants who are not able to perform the injections must receive assistance from a support person trained to administer the study intervention.
 - store and use the provided blinded study intervention, as directed
- ... and 2 more (see full listing online)

Exclusion (4)

- Have evidence of current or within the past 180 days prior to screening (V1), history of any substance use disorder(s) of any severity with a pattern of persistent illicit or nonprescribed substance use as indicated by clinical interview, except alcohol, nicotine, or caffeine.
- Have answered "yes" to either Question 4 or Question 5 on the "Suicidal Ideation" portion of the Columbia-Suicide Severity Rating Scale (C-SSRS) and the ideation occurred within the past 6 months, or Have answered "yes" to any of the suicide-related behaviors on the "Suicidal Behavior" portion of the C-SSRS and the behavior occurred within the past 6 months
- Have a history of advanced liver disease (including advanced liver fibrosis or cirrhosis), or alcohol associated hepatitis based on either prior liver histology or imaging studies, such as transient elastography, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), or Enhanced Liver Fibrosis score.
- Have participated in a clinical study and have received active treatment, or unknown if they received active treatment, within 90 days or 5 half-lives (whichever is longer) before screening (V1).

Locations (115 total)

Parkway Medical Center, Birmingham, Alabama, United States
Headlands Research - Scottsdale, Scottsdale, Arizona, United States
Woodland International Research Group, Little Rock, Arkansas, United States
... and 112 more locations

<https://clinicaltrials.gov/study/NCT07219953>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).